A whole-body vibration program in type 2 diabetic patients

Completed

Conditions: Diabetes type 2
Nutritional, Metabolic, Endocrine
Non-insulin-dependent diabetes mellitus

Registration Number: ISRCTN16866781

Lead Sponsor: niversity of Extremadura (Spain)

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: All

Target Recruitment: 90

Inclusion Criteria

1. Male and female, 40 to 85 years old, diagnosed with type 2 diabetes
2. Agreement to volunteer for the study by giving a written informed consent

Exclusion Criteria

1. Contraindications to high intensity exercise participation:
1.1. Retinopathy
1.2. Musculoskeletal limitations
1.3. Severe balance impairments
1.4. High risk of thrombosis
2. Psychotropic and neurotoxic drugs intake
3. Exposure to neurotoxins (industrial accidents, contact with toxic dumps)
4. Radiotherapy treatment
5. High risk of non-diabetic neuropathy (AIDS, uremia, alcoholism)
6. People who have or have had a job with high exposure to whole-body mechanical vibration
7. Individuals undergoing or have completed a whole-body vibration program

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. HbA1c. Measured with laboratory blood analysis at baseline and two months.<br>2. Vibration threshold. Measured with biothensiometer (vibraton II) at baseline, acute effects, one month and two month.

Secondary Outcome Measures

Name	Time	Method
1. Health related quality of life. Measured with EQ-5D-5L; SF-12; 15-D, Diabetes Quality of Life Measure (DQOL) and Foot Health Status Questionnaire (FHSQ). Measured at baseline and two months.<br>2. Balance. Measured with plate force (Romberg test open and closed eyes), Time and Go test (TUG). Measured at baseline and two months.<br>3. Strength. Measured with Chair and stand test, BMI, Tilts and stadiometer (Soehnle professional). Measured at baseline and two months.<br>4. Muscular and Fat percentage. Measured with impedance meter (Tanita) at baseline and two months.<br>5. Blood pressure. Measured with doppler at baseline and two months.<br>6. Lipidic profile. Measured with laboratory blood analysis at baseline and two months.<br>7. Diabetic neuropathy. Measured with Michigan Neuropathy Screening Instrument and monofilament at baseline and two months.<br>8. Body mass index (BMI). Measured at baseline and two months.